Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings

BACKGROUND: The most common site of disease in metastatic castration‐resistant prostate cancer (mCRPC) is the bone. The ALSYMPCA study demonstrated that radium‐223 significantly improved overall survival (OS) in mCRPC patients with symptomatic bone metastases and without visceral metastases. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, Oliver, Appukkuttan, Sreevalsa, Weiss, Jeffrey, Tsao, Che‐Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251844/
https://www.ncbi.nlm.nih.gov/pubmed/33978244
http://dx.doi.org/10.1002/pros.24143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251844/
https://www.ncbi.nlm.nih.gov/pubmed/33978244
http://dx.doi.org/10.1002/pros.24143

Ejemplares similares